|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
The Auto Beat
Byte of the Apple
Europe Insight
Eye on Asia
Getting In
Investing Insights
The New Entrepreneur
NEXT: Innovation Tools & Trends
On Media
Technology at Work
The Tech Beat
Traveler's Check
TECHNOLOGY
Product Reviews
Tech Stats
Hands On
AUTOS
Home Page
Auto Reviews
Car Care & Safety
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip FINANCE Investing: Europe Annual Reports Bloomberg BW50 SCOREBOARDS Hot Growth Companies: 2008 Mutual Funds Info Tech 100 B-SCHOOLS Undergrad Programs Rankings & Profiles |  |
MARCH 5, 2007
What Glaxo Saw In Epix 
When EPIX pharmaceuticals (EPIX
) (EPIX), a small biotech, signed up on Dec. 12 with GlaxoSmithKline (GSK
) for clinical trials of a drug for Alzheimer's and three other products, its stock leaped from 5.52 to 7.38 in two days. It has since eased to 6.49, but some pros think it will more than double in a year. The deal gave Glaxo 14.6% of Epix. Other funds focused on biotechs also have big positions, including OrbiMed Advisors, the No.2 investor, with 11.5%. Glaxo paid Epix an initial $35 million, with a potential of rising to $1.2 billion in milestone payments. "Its pipeline of internally developed compounds makes Epix attractive at current prices," says George Fulop of Needham, who has a 12-month target of 13. Max Jacobs of Mehta Capital, which owns shares, says Epix could hit 20 in two to three years based on the potential of its products.
Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By Gene G. Marcial Get BusinessWeek directly on your desktop with our RSS feeds.  Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2007, Bloomberg L.P.Terms of Use | Privacy Notice |
Printer-Friendly Version